Sumitomo Pharma Co Ltd
TSE:4506
Sumitomo Pharma Co Ltd
TSE:4506
Price:
339 JPY
0.89%
Market Closed
Updated:
May 21, 2024
EV/EBITDA
Enterprise Value to EBITDA
Enterprise Value to EBITDA
-1.8
Current
3.8
Median
13.7
Industry
Lower
than median
Lower
than industry value
Enterprise Value to EBITDA (EV/EBITDA) ratio is a valuation multiple that compares the value of a company, debt included, to the company’s cash earnings less non-cash expenses. EBITDA can be misleading at times, especially for companies that are highly capital intensive.
EV/EBITDA
=-1.8
Enterprise Value
/
276.1B
EBITDA
-157.4B
All Countries
| Market Cap | EV/EBITDA | ||||
|---|---|---|---|---|---|
| JP |
|
Sumitomo Pharma Co Ltd
TSE:4506
|
134.7B JPY | -1.8 | |
| JP |
N
|
Nichi-Iko Pharmaceutical Co Ltd
TSE:4541
|
776 550.9T JPY | -5 459 134.4 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
744.3B USD | 59.4 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
4T DKK | 33.6 | |
| UK |
|
Dechra Pharmaceuticals PLC
LSE:DPH
|
440.4B GBP | 3 846.3 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
364.1B USD | 11.7 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
331.8B USD | 35.8 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
187.5B GBP | 174.5 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
189B CHF | 9.3 | |
| CH |
|
Novartis AG
SIX:NOVN
|
182.7B CHF | 8.7 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
161.7B USD | 12.7 |
EV/EBITDA Forward Multiples
Forward EV/EBITDA multiple is a version of the EV/EBITDA ratio that uses forecasted EBITDA for the EV/EBITDA calculation. 1-Year, 2-Years, and 3-Years forwards use EBITDA forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
EV/EBITDA
-2.8
2-Years Forward
EV/EBITDA
22.7
3-Years Forward
EV/EBITDA
10.9
You don't have any saved screeners yet
